Mangalam Drugs & Organics Share Price Today | Stock Price & Mangalam Drugs & Organics Share Screener
As of October 5, 2026, the live Mangalam Drugs & Organics share price (NSE: MANGALAM) is ₹29.19 on NSE and ₹29.83 on BSE, up 0.14% from the previous close, with shares trading between ₹28.00 and ₹30.12 in today's trading session, and a 52-week range of ₹23.78–₹70.15. Check MANGALAM annual price range for the annual price range and momentum. Use the Mangalam Drugs & Organics stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Mangalam Drugs & Organics opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹67 and net income of ₹-13, with EBITDA of ₹-6, an operating margin of -8.0% and a profit margin of -19.4%.
Mangalam Drugs & Organics Share Price Chart
Track the current stock price of Mangalam Drugs & Organics with an interactive chart. Analyse MANGALAM share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Mangalam Drugs & Organics stock quote in one place.
The quote of ₹29.19 sits between the 52-week low of ₹23.78 and the 52-week high of ₹70.15, and the latest session moved 0.14% from the previous close.
Mangalam Drugs & Organics Company Profile - Fundamental Screener
Screen Mangalam Drugs & Organics company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for MANGALAM shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE584F01014.
Company Details
Classification
Identifiers and Leadership
Mangalam Drugs & Organics Balance Sheet Screener
Screen MANGALAM balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹315, down from ₹366 in 2025.
Latest statistics put total assets at ₹315 and shareholder funds at ₹103, with a leverage ratio of 0.73.
| Item | 2026 | 2025 | 2024 |
|---|---|---|---|
Assets |
|||
| Total Assets | 315 | 366 | 334 |
| Current Assets | 156 | 199 | 176 |
| Fixed Assets | 159 | 163 | 148 |
Liabilities |
|||
| Total Liabilities | 0 | 0 | 0 |
| Current Liabilities | 15 | 26 | 34 |
| Non-Current Liabilities | 0 | 0 | 0 |
Shareholders' Equity |
|||
| Total Equity | 103 | 149 | 136 |
| Share Capital | 16 | 16 | 16 |
| Reserves & Surplus | 87 | 133 | 120 |
Mangalam Drugs & Organics Income Statement Screener - Profit & Revenue Analysis
Screen Mangalam Drugs & Organics income statement and profit fundamentals. Analyze MANGALAM quarterly results. Mangalam Drugs & Organics reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Mar, revenue was ₹67 and net profit was ₹-13, equal to earnings per unit of ₹-8.48, at an operating margin of -8%.
In that period expenses were ₹73, interest cost ₹3 and tax ₹0. The next period listed, 2026-Jun, shows revenue of ₹57 and net profit of ₹-8.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||
| Revenue | 67 | 57 | 73 | 57 | 49 | 59 | 102 | 77 | 80 | 89 | 97 |
| Expenses | 73 | 56 | 63 | 62 | 52 | 60 | 91 | 68 | 71 | 80 | 90 |
Operating Costs and Margins | |||||||||||
| EBITDA | -6 | 1 | 10 | -5 | -3 | -1 | 12 | 8 | 9 | 9 | 7 |
| Operating Profit % | -8.00% | 2.00% | 14.00% | -8.00% | -6.00% | -3.00% | 11.00% | 11.00% | 11.00% | 10.00% | 7.00% |
| Depreciation | 5 | 4 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 4 | 4 |
| Interest | 3 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 4 | 4 | 3 |
Profit and Earnings | |||||||||||
| Profit Before Tax | -13 | -7 | 2 | -13 | -13 | -10 | 4 | 1 | 1 | 1 | 0 |
| Tax | 0 | 1 | 2 | 1 | -5 | 0 | 0 | -2 | -2 | 0 | -1 |
| Net Profit | -13 | -8 | 0 | -14 | -7 | -10 | 4 | 3 | 3 | 1 | 1 |
| EPS | -8.48 | -4.83 | 0.04 | -8.72 | -4.64 | -6.21 | 2.23 | 1.70 | 1.70 | 0.81 | 0.31 |
Mangalam Drugs & Organics Cash Flow Screener - Liquidity Fundamentals
Screen MANGALAM cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2025-March, operating activities generated ₹43, and net cash flow was an inflow of ₹1.
Over the same period, investing activities used ₹20 and financing activities used ₹22.
| Item | 2025-March | 2024-March |
|---|---|---|
Cash from Operations and Investing | ||
| Operating Activities | 43 | 4 |
| Investing Activities | -20 | -12 |
Financing and Net Cash | ||
| Financing Activities | -22 | 5 |
| Net Cash Flow | 1 | -3 |
Mangalam Drugs & Organics Shareholding Pattern Screener
See Mangalam Drugs & Organics shareholding pattern with promoter, FII, and DII holdings. Check Mangalam Drugs & Organics promoter holding and ownership changes for MANGALAM on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Jun, promoters held 35.65%, foreign institutions 0.11%, domestic institutions 0.00% and the public 60.51%, spread across 24,465 shareholders.
The shareholder count was 24,465 in 2026-Jun, compared with 25,140 in 2026-Mar.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 35.65% | 35.65% | 35.64% | 50.30% | 50.30% | 50.30% | 50.30% | 50.30% |
Institutional Investors | ||||||||
| FII Holding | 0.11% | 0.32% | 0.13% | 0.11% | 0.53% | 0.47% | 0.11% | 0.11% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 60.51% | 60.14% | 57.52% | 45.00% | 44.53% | 44.55% | 44.78% | 44.91% |
| Other Holding | 3.73% | 3.89% | 6.70% | 4.59% | 4.63% | 4.68% | 4.80% | 4.67% |
| Shareholder Count | 24,465 | 25,140 | 21,227 | 19,881 | 19,728 | 19,697 | 19,679 | 19,508 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Mangalam Drugs & Organics. Mangalam Drugs & Organics dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹0.00 per unit for 2026-March, a yield of 0.00%, compared with ₹0.00 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹0.00, ₹0.00 and ₹0.00 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.50 | 0.92% |
| 2017-March | ₹0.00 | 0.00% |
Mangalam Drugs & Organics Stock Index Membership - Nifty & Sensex
See which indices include Mangalam Drugs & Organics stock. Check MANGALAM index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Mangalam Drugs & Organics Market Events Screener - Corporate Actions
Get Mangalam Drugs & Organics corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Mangalam Drugs & Organics stock events that may affect MANGALAM share price, along with derivatives, futures and options activity and sector gainers.
12 corporate actions are listed, the most recent entry being Annual General Meeting dated September 23, 2026, with a record date of September 23, 2026.
It is followed by Quarterly Result Announcement dated August 12, 2026 and Quarterly Result Announcement dated May 14, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-23 | 2026-09-23 | Annual General Meeting | NA | 1.54% |
| 2026-08-12 | 2026-08-12 | Quarterly Result Announcement | NA | -1.35% |
| 2026-05-14 | 2026-05-14 | Quarterly Result Announcement | NA | 3.97% |
| 2026-01-15 | 2026-01-15 | Quarterly Result Announcement | NA | 33.96% |
| 2025-11-20 | 2025-11-20 | Quarterly Result Announcement | NA | -17.31% |
| 2025-09-29 | 2025-09-29 | Annual General Meeting | NA | -7.92% |
| 2025-08-12 | 2025-08-12 | Extraordinary General Meeting | NA | -9.85% |
| 2025-08-07 | 2025-08-07 | Quarterly Result Announcement | NA | -4.03% |
| 2025-05-17 | 2025-05-17 | Quarterly Result Announcement | NA | 4.63% |
| 2025-02-13 | 2025-02-13 | Quarterly Result Announcement | NA | 1.61% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -4.83% |
| 2024-09-26 | 2024-09-26 | Annual General Meeting | NA | -4.57% |
Mangalam Drugs & Organics Competitors Screener - Peer Stocks Comparison
Screen MANGALAM competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 440,998 | 36.70 | 61,674 | 12.69% | 11,565 | 40.74 |
| Divis Laboratories | 253,522 | 87.22 | 11,067 | 13.95% | 2,568 | 63.87 |
| Torrent Pharmaceuticals | 185,201 | 87.95 | 13,886 | 20.34% | 2,138 | 46.50 |
| Zydus Life Science | 122,257 | 26.11 | 27,658 | 17.64% | 5,026 | 66.57 |
| Cipla | 111,782 | 33.64 | 29,045 | 2.24% | 3,870 | 45.42 |
| Laurus Labs | 108,549 | 99.16 | 6,868 | 22.01% | 890 | 64.04 |
| Dr Reddys Laboratories | 101,913 | 31.54 | 35,059 | 3.90% | 4,158 | 63.11 |
| Mankind Pharma | 100,589 | 49.45 | 14,636 | 14.85% | 1,938 | 55.24 |
| Aurobindo Pharma | 97,670 | 26.54 | 34,145 | 5.56% | 3,503 | 54.66 |
| Lupin | 94,281 | 17.22 | 29,039 | 26.75% | 5,356 | 35.30 |
Mangalam Drugs & Organics Company Announcements - News & Reports Screener
Screen MANGALAM latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated .
The next most recent announcements are dated October 3, 2026 and October 2, 2026.
| Date | Update | Actions |
|---|---|---|
| Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A | - | |
| 2026-10-03 | Closure of Trading Window | - |
| 2026-10-02 | Announcement under Regulation 30 (LODR)-Retirement | - |
| 2026-10-02 | Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s | - |
| 2026-10-02 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-10-02 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-10-01 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-09-15 | Defaults under Para A sub-paragraph 6 of Schedule III-Subsequent Disclosure | - |
| 2026-09-15 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-09-15 | Board Meeting Outcome for Outcome Of Board Meeting Pursuant To Regulation 30 Of LODR For Appointment Of Mr. Prabhakar Zavar As Additional Indepedent Director ( Non-Executive) For Term Of 5 Years Wef. 15/09/2026 Subject To Consent Of Shareholders At Ensuin | - |
| 2026-09-01 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-31 | Reg. 34 (1) Annual Report. | - |
| 2026-08-31 | Intimation Of 53Rd Annual General Meeting To Be Held On Wednesday September 23Rd 2026. | - |
| 2026-08-17 | Defaults under Para A sub-paragraph 6 of Schedule III-Subsequent Disclosure | - |
| 2026-08-13 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-12 | Appointment Of Secretarial Auditor Of The Company For Term Of 5 Years Subject To Approval Of Shareholders In Ensuing 53Rd Annaul General Meeting Of The Company | - |
| 2026-08-12 | Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s | - |
| 2026-08-12 | Declaration Of Un-Audited Financial Results (Standalone & Consolidated) For The Quarter Ended 30Th June 2026 | - |
| 2026-08-12 | Board Meeting Outcome for Outcome Of Board Meeting Held On 12Th August 2026 Interalia For Approval Of Un-Audited Financial Results (Standalone & Consolidated) For The Quarter Ended 30Th June 2026 | - |
| 2026-08-06 | Intimation Of Resignation Tendered By Ragini Chokshi & Co. Secretarial Auditor Of The Company W.E.F. 4Th August 2026. | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹29.19, within a 52-week range of ₹23.78 to ₹70.15. The P/E ratio is -1.32 and the P/B ratio is 0.53, with earnings per unit of ₹-28.05. Market capitalisation stands at ₹48.91 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 6, 2026. This page covers 3 balance sheet periods, 11 income statement periods, 2 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.